BlueCross BlueShield of Tennessee Medical Policy Manual

Prostate Specific Antigen (PSA)

DESCRIPTION

The prostate specific antigen (PSA) test measures serum levels of the prostate cancer-associated antigen. The test is used to monitor for progression or regression of prostate cancer after therapy. Although increased serum PSA can be an early indicator of prostate cancer, other conditions such as benign prostatic hypertrophy (BPH) can also cause an elevation in the serum PSA level.

POLICY

MEDICAL APPROPRIATENESS

APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS

The provisions of this mandate concerning early detection of prostate cancer, Tennessee Code Annotated, Title 56, Chapter 7, Part 2354 read as follows:

Health Benefit Plan

A)    Means a hospital or medical expense policy; health, hospital, or medical service corporation contract; policy or agreement entered into by a health insurer; or health maintenance organization contract offered by an employer.

B)    Includes a state insurance plan set out in title 8, chapter 27; a policy or contract for health insurance coverage provided under the TennCare medical assistance program or a successor program provided for in title 71, chapter 5; and a policy or contract of health insurance coverage provided under the CoverKids program, or a successor program provided for in title 71, chapter 3.

“Men with a family history of prostate cancer” means men who have a first-degree relative:

A)    Who was diagnosed with prostate cancer;

B)    Who developed prostate cancer;

C)    Whose death was a result of prostate cancer;

D)    Who has been diagnosed with a cancer known to be associated with an increased risk of prostate cancer; or

E)    Who has a genetic alteration known to be associated with an increased risk of prostate cancer

A health benefit plan shall provide, upon the recommendation of a physician, coverage for the early detection of prostate cancer for:

1)    Men forty (40) to forty-nine (49) years of age who are at a high risk of developing prostate cancer, including African-American men, and men with a family history of prostate cancer;

2)    Men fifty (50) years of age and older; and

3)    Other men if a physician determines that early detection for prostate cancer is medically necessary

IMPORTANT REMINDERS

SOURCES

Tennessee Code: Title 56 Insurance. Chapter 7 Policies and Policyholders: Part 23 Mandated Insurer or Plan Coverage, 56-7-2354. Early detection of prostate cancer. Received from BCBST’s Legal Division on May 23, 2024. 

U. S. Preventive Services Task Force. (2018, May). Screening for prostate cancer: U.S. preventive services task force recommendation statement. Retrieved November 2, 2018 from https://www.uspreventiveservicestaskforce.org.

ORIGINAL EFFECTIVE DATE:  7/1995

MOST RECENT REVIEW DATE:  7/1/2024

ID_BT

Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.

This document has been classified as public information.